🔎 Trials Near Me

Pradžia › Krono liga › Ohio

Krono liga klinikiniai tyrimai Ohio

30 tyrimai dėl Krono liga ieško dalyvių vietose Ohio.

Miestai Ohio

Oficialus tyrimo tekstas (anglų kalba)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-10-02 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07697456

Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07852273

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Gastro Health Research - Cincinnati, Cincinnati
  • DSI Research Northridge LLC, Dayton
  • Gastro Health Research - Liberty Township, Liberty Township
  • ir dar 3
Renkami dalyviai4 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-30 · NCT06581328

Non-nutritive Sweeteners in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07769437

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • University of Cincinnati /ID# 265589, Cincinnati
  • The Ohio State University /ID# 265577, Columbus
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07499232

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Renkami dalyviai3 fazė
Amžius 3 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06663332

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
  • University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
  • Ohio Gastroenterology Group Inc.-8400006, Columbus
  • ir dar 5
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
  • Medical Associates Research Group-Site Number: 8400063, Columbus
  • OSU Wexner Medical Center-Site Number: 8400077, Columbus
  • ir dar 1
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Cleveland Clinic - Cleveland /ID# 256453, Cleveland
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-09-23 · NCT05995353

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • University of Cincinnati, Cincinnati
  • Ohio Gastroenterology group, Inc., Columbus
  • Great Lakes Gastroenterology Research, LLC, Mentor
  • ir dar 1
Renkami dalyviai4 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-09 · NCT06045754

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07577843

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

  • Cleveland Clinic, Cleveland
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-27 · NCT07680283

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Childrens Medical Center, Dayton
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-08-24 · NCT05509777

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of Cincinnati, Cincinnati
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-05 · NCT07237516

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • UH Cleveland Medical Center /ID# 262188, Cleveland
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-06-24 · NCT06332534

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Children's Clinic, Cleveland
  • Cleveland Clinic, Cleveland
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-06-22 · NCT06405087

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • UH/Rainbow Babies and Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
Renkami dalyviai4 fazė
Amžius nuo 6 iki 17 · Visoms lytims · Atnaujinta 2026-05-27 · NCT05781152

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Renkami dalyviai3 fazė
Amžius 2 ir vyresni · Visoms lytims · Atnaujinta 2026-05-07 · NCT05442567

Precise Infliximab Exposure and Pharmacodynamic Control

  • Cincinnati Children's Hospital, Cincinnati
  • Cleveland Clinic Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
Renkami dalyviai2/3 fazė
Amžius nuo 6 iki 22 · Visoms lytims · Atnaujinta 2026-05-05 · NCT05660746

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-05-05 · NCT04779320

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • OSU Inflammatory Bowel Disease Center, Hilliard
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-04-27 · NCT06456593

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Cincinnati
  • Mirador Therapeutics Selected Site, Liberty Township
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-03-12 · NCT07113522

Treatment of Moderate to Severe Refractory Crohn's Disease

  • Cleveland Clinic, Cleveland
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2025-12-10 · NCT06721962

Evaluation of the SMART IBD App in Pediatric IBD

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Renkami dalyviai
Amžius nuo 13 iki 17 · Visoms lytims · Atnaujinta 2025-11-21 · NCT07195123

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

  • Cleveland Clinic Foundation, Cleveland
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-11-12 · NCT06670638

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.